Prelude Therapeutics (PRLD) Q1 2026 Earnings
Prelude Therapeutics reported Q1 2026 revenue of $4.6M. Diluted EPS came in at $-0.13 (+69.0% YoY), beat the $-0.27 consensus by $0.14.
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Prelude Therapeutics's Q1 2026 earnings report.
Prelude Therapeutics (PRLD) reported Q1 2026 earnings on May 12, 2026 before market open.
Prelude Therapeutics reported revenue of $4.6M and diluted EPS of $-0.13 for Q1 2026.
Revenue beat the consensus estimate of $4.6M by -. EPS beat the consensus estimate of $-0.27 by $0.14.
Compared to the same quarter a year prior, diluted EPS grew 69.0% from $-0.42.
You can read the 8-K earnings release (0001193125-26-218162) and the 10-Q periodic report (0001193125-26-218173) directly on SEC EDGAR. The filing index links above go to sec.gov.